Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Size, Share & Trends Analysis Report By Device Type (Endovascular Devices, Surgical Devices), By Procedure, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Aorto-Iliac Occlusive Disease Treatment Market Summary

The increasing prevalence of Peripheral Artery Disease (PAD) is one of the key factors driving the market's growth. According to the American Heart Association, Inc. article published in June 2023, Peripheral artery disease (PAD) affects an estimated 200 million people worldwide. It significantly contributes to developing Aorto-Iliac Occlusive Disease (AIOD). The growing prevalence of PAD, driven by factors such as aging populations, diabetes, and smoking, has increased the need for effective treatments for AIOD. This rising demand drives the adoption of minimally invasive procedures, including iliac artery stenting and endovascular therapies, which help restore proper blood flow and alleviate symptoms like leg pain and limited mobility.

Increasing government initiatives drive the market growth. According to the Congress.Gov article published in June 2023, the U.S. government took a significant step toward enhancing early detection and management of Peripheral Artery Disease (PAD), a primary contributor to Aorto-Iliac Occlusive Disease, through the introduction of the Arterial and Venous Comprehensive (ARC) Act. This legislation proposes amendments to the Social Security Act, aiming to ensure that Medicare and Medicaid beneficiaries identified as high-risk can access PAD screening without incurring out-of-pocket costs. Covered diagnostic procedures include ankle-brachial index (ABI) tests and arterial duplex scans, critical for identifying PAD and assessing disease severity in the aorto-iliac region. Authorizing USD 6 million in annual funding from 2024 to 2028, the ARC Act seeks to improve early diagnosis and timely intervention, potentially reducing the burden of advanced occlusive conditions and boosting the demand for targeted treatment options such as iliac stenting and revascularization therapies. This initiative promotes preventive care and supports broader access to essential vascular health services.

Moreover, as per the American College of Cardiology Foundation. Article published in February 2025, the Sustainable Cardiopulmonary Rehabilitation Services in the Home Act (H.R. 783), recently reintroduced, proposes to make the Medicare coverage for in-home cardiopulmonary rehabilitation services permanent. This legislative move is designed to enhance access to essential rehabilitation, especially for patients with mobility limitations or those residing in remote areas. Facilitating easier access to rehabilitation care, this initiative supports the effective management of peripheral artery disease (PAD) and related conditions, including Aorto-Iliac Occlusive Disease, ultimately improving patient outcomes and driving demand for advanced treatment options in the market.

Technological advancements in aorto-iliac occlusive disease (iliac disease) treatment drive the market's growth. For instance, in January 2025, Bentley Medical introduced the BeFlow iliac covered stent system at the Leipzig Interventional Course (LINC) 2025, marking a significant advancement in treating aorto-iliac occlusive disease. Designed to address complex iliac lesions, the BeFlow stent offers enhanced long-term patency and durability, aligning with European Society for Vascular Surgery guidelines that recommend covered stents for heavily stenosed or occluded iliac arteries. Available in diameters ranging from 7 to 10 mm and lengths of 37 and 57 mm, the BeFlow stent aims to provide a cost-effective alternative to bare metal stents, improving patient access to advanced vascular interventions.

Market Concentration & Characteristics

The aorto-iliac occlusive disease (iliac disease) treatment industry is experiencing notable innovation driven by next-generation endovascular technologies. Advancements include image-guided stent deployment systems, drug-eluting stents tailored for iliac anatomy, and precision-engineered balloon-expandable and self-expanding stents that improve flexibility and radial strength. In addition, hybrid techniques integrating real-time 3D imaging and robotic-assisted navigation improve procedural precision and outcomes in complex cases.

Key players in the aorto-iliac occlusive disease (iliac disease) treatment industry, including Medtronic, Abbott, and Boston Scientific Corporation, are actively pursuing mergers, acquisitions, and strategic collaborations to strengthen their market position. These efforts aim to accelerate the development of advanced endovascular devices, expand global distribution networks, and integrate innovative technologies such as drug-coated balloons and next-generation stent systems. By enhancing their product portfolios and clinical capabilities, these companies are better positioned to meet the rising demand for minimally invasive and effective treatment options for complex aorto-iliac occlusive conditions, ultimately improving patient outcomes and procedural safety.

Regulatory bodies like the FDA and EMA play a key role in shaping the aorto-iliac occlusive disease treatment industry by ensuring the safety and effectiveness of medical devices. While approval processes can be lengthy, initiatives such as fast-track approvals and innovation-friendly policies are helping accelerate the entry of advanced technologies like drug-eluting stents and imaging-guided systems, supporting market growth.

There are no direct substitutes for aorto-iliac occlusive disease treatment procedures, as they are essential for restoring adequate blood flow to the lower limbs. Although lifestyle changes and pharmacological therapies can help manage symptoms, they do not offer the revascularization benefits of endovascular or surgical interventions.

Key players in the aorto-iliac occlusive disease treatment industry are expanding their presence by offering specialized training for clinicians, partnering with regional health institutions, and tailoring intervention strategies to address the unique clinical demands of underserved populations. These efforts aim to improve access to advanced endovascular and surgical solutions, enhance treatment outcomes, and support early diagnosis and intervention in regions with limited vascular care infrastructure.

Device Type Insights

The endovascular devices segment led the market with the largest revenue share of 87.5% in 2024. Endovascular devices are specialized medical tools used to treat vascular diseases by accessing and repairing blood vessels from within, typically through minimally invasive catheter-based techniques. Endovascular devices play a crucial role in the minimally invasive treatment of Aorto-Iliac Occlusive Disease (AIOD), offering alternatives to traditional open surgery. These devices include balloon angioplasty systems, various stent types (such as self-expanding, balloon-expandable, and covered stents), and atherectomy systems, all designed to restore proper blood flow through narrowed or blocked arteries. Technological advancements have significantly improved the safety and efficacy of these devices.

For instance, in April 2024, Getinge’s Advanta V12 covered stent system recently received certification under the European Union Medical Device Regulation (EU MDR), confirming its suitability for treating patients with aortoiliac occlusive disease, including complex lesions at the aortic bifurcation. This regulatory milestone highlights the system’s compliance with rigorous safety and performance standards, enabling wider clinical adoption across Europe.

The balloon angioplasty devices segment is expected to grow at the fastest CAGR during the forecast period, owing to the increasing incidence of PAD and the technological advances in product launches, which drive the development of the market. Balloon-expandable stents are specialized vascular implants delivered to the target vessel using a balloon catheter. Once properly positioned, the balloon is inflated to expand the stent, pressing it against the arterial wall to restore blood flow. These stents provide precise placement and high radial strength, making them particularly suitable for treating lesions in large-caliber vessels like the iliac arteries. For instance, in February 2024, W. L. Gore & Associates received FDA approval for its low-profile VBX balloon-expandable stent graft. Designed for treating de novo or restenotic lesions in the iliac artery, this stent accommodates vessel diameters from 5 to 13 mm and lesion lengths up to 110 mm. The device's reduced profile allows compatibility with 6-French sheaths, facilitating procedures in patients with challenging anatomies. The VBX stent graft has demonstrated favorable long-term outcomes, with ongoing studies comparing its performance to bare-metal stents in complex iliac occlusive disease cases.

Procedure Insights

The endovascular procedures segment led the market with the largest revenue share of 61.1% in 2024, due to the increasing incidence of PAD diseases, government initiatives, and technological advancements. Artificial intelligence (AI) is increasingly being integrated into endovascular procedures, aiming to enhance precision, reduce procedural risks, and improve overall outcomes. Recent studies have explored AI-driven systems that assist in the autonomous navigation of catheters and guidewires, particularly utilizing reinforcement learning (RL) and imitation learning techniques.

According to the School of Biomedical Engineering & Imaging Sciences article published in May 2024, analyzed 14 studies focusing on AI applications in autonomous endovascular navigation. The review found that 64% of these studies employed reinforcement learning, while 50% utilized learning from expert demonstrations. These AI models were primarily tested on physical phantoms and in-silico models, demonstrating the potential to decrease operation times, enhance decision-making during surgery, and reduce operator radiation exposure. However, the review also noted that the field is currently at a technology readiness level of 3, indicating that these technologies are still in the experimental proof-of-concept stage and have not yet undergone clinical validation.

The hybrid procedures segment is anticipated to grow at the fastest CAGR during the forecast period, owing to the increasing prevalence of PAD and technological advancements, which drive the market's growth. Hybrid procedures integrate open femoral endarterectomy with endovascular recanalization and stenting of iliac occlusions to treat complex iliofemoral artery blockages.

According to the Elsevier Inc. article published in January 2023, a study involving 147 patients and 163 iliofemoral occlusions, this combined approach showed a high technical success rate of 88.3% and excellent primary patency rates of 98.7% at 30 days, 98.1% at 6 months, 96.6% at 1 year, and 93.7% at 2 years. Minimizing surgical trauma and reducing recovery time compared to traditional aortobifemoral bypass, hybrid procedures are especially beneficial for patients with significant comorbidities and complex lesions. The use of covered stents in nearly 34% of cases and the successful management of long occlusions highlight its versatility. Growing clinical evidence and guideline endorsements for hybrid revascularization in complex aorto-iliac occlusive disease are driving its increasing adoption in the market.

End Use Insights

The hospitals segment led the market with the largest revenue share of 49.2% in 2024. Hospitals are increasingly expanding their treatment portfolios to include advanced and minimally invasive procedures for managing complex aorto-iliac occlusive disease. For instance, NYU Langone Health has implemented minimally invasive procedures such as atherectomy and balloon angioplasty with stenting. These treatments are performed under local anesthesia, often allowing patients to return home the same day, thereby reducing hospital stays and accelerating recovery times. The integration of such procedures into hospital settings underscores a shift towards less invasive, patient-friendly interventions that maintain high efficacy in restoring blood flow and alleviating symptoms associated with AIOD

The outpatient facilities segment is expected to grow at the fastest CAGR during the forecast period. Outpatient refers to a type of medical care or treatment that does not require an overnight stay in a hospital or medical facility. Outpatients visit a clinic, hospital, or healthcare center for diagnosis, treatment, or minor procedures and return home the same day. Outpatient facilities are also expanding their capabilities to treat AIOD, offering patients convenient access to effective therapies without the need for hospitalization.

At Tampa General Hospital, for example, certain endovascular treatments for AIOD are conducted in outpatient settings, utilizing techniques like angioplasty and stenting to reopen narrowed arteries. This approach not only enhances patient comfort by minimizing hospital exposure but also optimizes resource utilization within the healthcare system. The success of such outpatient interventions reflects a broader trend of decentralizing vascular care, making advanced treatments more accessible to a wider patient population.

Regional Insights

North America dominated the aorto-iliac occlusive disease (iliac disease) treatment market with the largest revenue share of 43.5% in 2024. The rising incidence of PAD, increased government initiatives, and technological advancements drive the market's growth. According to the Science Direct article published in March 2025, it is estimated that around 6.5 million individuals aged 40 years and above are affected, representing approximately 5.8% of this population group. Additionally, the annual incidence rate of PAD is approximately 2.69%, reflecting the steady rise in new cases each year. These trends highlight the increasing need for effective diagnostic and treatment solutions in the U.S. aorto-iliac occlusive disease treatment industry, as healthcare systems work to address the complications and risks associated with age-related vascular conditions.

U.S. Aorto-iliac Occlusive Disease Treatment Market Trends

The aorto-iliac occlusive disease (iliac disease) treatment market in the U.S. accounted for the largest market revenue share in North America in 2024. Increasing PAD incidence and technological advancements drive the market growth. For instance, in November 2024, Philips launched a clinical trial in the U.S. to evaluate a novel device that merges laser atherectomy with intravascular lithotripsy in a single catheter system. This innovative approach aims to more effectively treat complex, calcified lesions commonly seen in patients with peripheral artery disease (PAD), which includes those with aorto-iliac occlusive disease. The first successful procedure was performed on a 78-year-old male patient at the Cardiovascular Institute of the South in Louisiana, marking a promising advancement in minimally invasive treatment strategies. Integrating plaque modification technologies into one device, the system has the potential to simplify procedures, reduce operating time, and improve outcomes, particularly in challenging iliac artery cases.

Europe Aorto-iliac Occlusive Disease Treatment Market Trends

The aorto-iliac occlusive disease (iliac disease) treatment market in Europe held the second-largest revenue market share in 2024. The increasing incidence of PAD and government initiatives drive the market growth. According to an NCBI article published in December 2024, PAD was diagnosed in 941 individuals. The prevalence of PAD was significantly higher among European patients, affecting 8.1% of this group. This elevated PAD burden in Europe directly emphasizes the growing demand for effective aorto-iliac occlusive disease treatments.

The Germany aorto-iliac occlusive disease (iliac disease) treatment market is anticipated to grow at a significant CAGR over the forecast period. The increasing incidence of PAD and the technologically advanced products offered by the key players drive the growth of the market. According to a Hogrefe article published in October 2023, Peripheral artery disease (PAD) impacts an estimated 15-20% of the German population, with prevalence rates steadily increasing in recent years. This growing incidence reflects broader trends in cardiovascular health challenges within the country, driving a heightened need for effective management of related conditions such as aorto-iliac occlusive disease. PAD frequently involves blockages in the iliac arteries. Germany’s expanding patient population underscores the demand for advanced treatment options, including minimally invasive endovascular therapies and surgical interventions, to address the complexities of iliac artery disease and improve clinical outcomes.

The aorto-iliac occlusive disease (iliac disease) treatment market in the UK held the second-largest market share in Europe in 2024. The rising incidence of PAD and technological advancements drive the growth of the market. According to the British Heart Foundation article published in August 2024, in the UK, approximately 20% of individuals aged 60 and above are affected by peripheral artery disease (PAD), highlighting a significant health concern among the aging population. The primary risk factors driving PAD, smoking, diabetes, obesity, and hypertension, closely align with those linked to cardiovascular diseases such as heart disease and stroke. Given that aorto-iliac occlusive disease is a common and serious manifestation of PAD, this prevalence signals a growing need for effective treatment solutions in the UK. Addressing these underlying risk factors and advancing therapeutic options for iliac artery disease will be crucial in managing the disease burden and improving patient outcomes across the country.

The France aorto-iliac occlusive disease (iliac disease) treatment market is anticipated to witness at a significant CAGR of 5.9% during the forecast period. The increasing incidence of PAD and technological advances drive the market's growth. According to the Elsevier B.V. article published in June 2024, Peripheral artery disease (PAD) affects up to one-fifth of the population in France, reflecting a substantial public health challenge. Studies indicate that among individuals with one or more cardiovascular risk factors, approximately 12.2% have asymptomatic PAD, often detected through ankle-brachial index screening. This prevalence underlines the importance of early diagnosis and intervention, particularly for aorto-iliac occlusive disease, a severe form of PAD affecting the iliac arteries.

Asia Pacific Aorto-iliac Occlusive Disease Treatment Market Trends

The aorto-iliac occlusive disease (iliac disease) treatment market in Asia Pacific is expected to grow at the fastest CAGR during the forecast period. Key aspects such as rapidly increasing prevalence of peripheral artery disease (PAD), rising awareness about vascular health, expanding healthcare infrastructure, and improving access to advanced medical technologies are driving this growth. In addition, the region’s large and aging population, coupled with increasing rates of diabetes, obesity, and smoking, contributes to the growing demand for effective treatment options for iliac artery disease. These dynamics make the Asia Pacific a key focus area for market players and healthcare providers aiming to address the rising burden of aorto-iliac occlusive disease.

The China aorto-iliac occlusive disease (iliac disease) treatment market accounted for the largest market revenue share in the Asia Pacific in 2024. Rising PAD cases and technological advancements drive the growth of the market. According to the NCBI article published in August 2023, in China, peripheral artery disease (PAD) affects approximately 45.3 million people, underscoring a significant and growing healthcare challenge. This substantial patient population drives the urgent demand for effective treatment options, particularly for aorto-iliac occlusive disease, a critical manifestation of PAD. Advanced therapies, such as covered stents and other endovascular interventions, are increasingly sought after to address iliac artery blockages and improve patient outcomes. The awareness and diagnosis rates improve alongside healthcare infrastructure development, China’s market for aorto-iliac occlusive disease treatments is poised for significant expansion.

The aorto-iliac occlusive disease (iliac disease) treatment market in Japan accounted for the second largest market revenue share in the Asia Pacific in 2024. Increasing PAD cases, and strategic initiatives by the key players drive the market's growth. For instance, in November 2023, Penumbra Inc.’s Indigo system, designed for effective thrombus removal, received regulatory approval under the Japanese Pharmaceutical & Medical Device Act in April 2023. Following this, Penumbra entered into a definitive distribution agreement with Asahi Intecc Group, granting exclusive sales rights for the Indigo and Lightning systems through Asahi Intecc J-sales, Inc. This collaboration underscores the growing availability of advanced endovascular solutions in Japan, offering improved treatment options for patients suffering from iliac artery blockages and related vascular conditions.

The India aorto-iliac occlusive disease (iliac disease) treatment market is experiencing significant growth driven by the rising number of PAD cases in India and technological advancements. According to the Indian Journal of Indian College of Cardiology article published in August 2023, in India, peripheral artery disease (PAD) is emerging as a pressing public health issue, with prevalence rates estimated to range from 5% to as high as 25% among adults. The incidence is particularly elevated in older populations and individuals with underlying risk factors, such as diabetes and tobacco use-conditions that are becoming increasingly common in the country. This growing burden of PAD signals a rising demand for timely diagnosis and effective treatment strategies, especially for complex manifestations such as aorto-iliac occlusive disease.

Latin America Aorto-iliac Occlusive Disease Treatment Market Trends

The aorto-iliac occlusive disease (iliac disease) treatment market in Latin America is growing due to several factors. Rising PAD cases and technological advancements drive the market growth. According to the Pan American Health Organization article published in October 2024, In Latin America, particularly in countries like Argentina, the rising elderly population is significantly influencing the aorto-iliac occlusive disease (iliac disease) treatment market. In 2024, individuals aged 65 and older accounted for approximately 12.4% of Argentina’s total population, up from 9.6% in 2000 an increase of 2.8 percentage points. This demographic trend is contributing to a growing burden of age-related vascular conditions, including peripheral artery disease (PAD), thereby driving demand for effective treatment solutions and expanding the market for aorto-iliac disease interventions across the region.

The Brazil aorto-iliac occlusive disease (iliac disease) treatment market is witnessing steady growth, fueled by an increasing prevalence of peripheral artery disease (PAD) and a rising demand for minimally invasive treatment options. The country faces a growing burden of vascular diseases, particularly among aging populations and individuals with common risk factors such as diabetes, hypertension, and smoking. This has led to a greater emphasis on early diagnosis and intervention. Technological advancements in endovascular therapies, including angioplasty and stenting procedures, are enhancing treatment outcomes and supporting wider adoption across healthcare facilities.

MEA Aorto-iliac Occlusive Disease Treatment Market Trends

The aorto-iliac occlusive disease (iliac disease) treatment market in MEA is expected to grow at a lucrative CAGR during the forecast period, due to the economic development and improved healthcare facilities in the region have led to increased demand for advanced medical treatments. Countries like Saudi Arabia are witnessing a rise in peripheral artery disease (PAD) prevalence, estimated at 12%, which is contributing to the expansion of the iliac stents market. The presence of high unmet medical needs in emerging economies, such as South Africa, further propels market growth.

The Saudi Arabia aorto-iliac occlusive disease (iliac disease) treatment market is anticipated to grow at a substantial CAGR over the forecast period. Rising incidence of the PAD and technological advancement drives the market growth. According to a BioMed Central Ltd article published in March 2024, a recent study conducted in Saudi Arabia found that peripheral artery disease (PAD) affects approximately 11.7% of patients aged 45 years and older within a cohort of 471 individuals. The relatively high prevalence reported may be influenced by the study’s focused sample size and the older age group, which is generally at greater risk for vascular disorders. This highlights a significant patient population in need of effective aorto-iliac occlusive disease treatment options, underscoring the growing demand for advanced therapeutic interventions in Saudi Arabia. 

Key Aorto-Iliac Occlusive Disease Treatment Company Insights

Some of the key players operating in the industry include Boston Scientific Corporation, BD, and Abbott. The company’s key strategies include understanding the strengths and weaknesses of major market participants, anticipating future market trends, opportunities, and challenges, and making proactive decisions based on insights into emerging technologies and changing consumer preferences. For instance, Biotronik SE & Co KG and Getinge AB are some of the emerging players in the aorto-iliac occlusive disease (iliac disease) treatment industry.

Recent Developments

• In December 2024, Biotronik concluded the BIO-OSCAR SOC trial, a prospective, multicenter, observational study evaluating current standard of care practices in treating peripheral artery disease (PAD). The study aimed to assess procedural outcomes and device use in endovascular treatments for atherosclerotic lesions, providing insights into real-world practices for managing PAD.

• In March 2024, Cook Medical entered into an exclusive distribution agreement with Getinge for the iCast covered stent system in the U.S. This collaboration aims to enhance the availability and distribution of the device, which is indicated for the treatment of iliac arterial occlusive disease.

• In January 2024, Zylox-Tonbridge Medical Technology Co., Ltd. has received marketing approval from the National Medical Products Administration (NMPA) for its ZYLOX® Peripheral Venous Stent System. This innovative device is designed to address lower limb and pelvic venous return disorders caused by iliac vein compression, such as May-Thurner Syndrome. 

Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Report Scope

Global Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and analyzes the industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the global aorto-iliac occlusive disease treatment market report based on device type, procedure, end use, and region:

• Device Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Endovascular Devices

    • Balloon Angioplasty Devices

    • Atherectomy Systems

    • Stents

      • Self-Expanding Stents

      • Balloon-Expandable Stents

      • Covered Stent Grafts

      • Bifurcated Aortic Stent Grafts

  • Surgical Devices

• Procedure Outlook (Revenue, USD Million, 2018 - 2030)

  • Endovascular Procedures

    • Balloon Angioplasty

    • Primary Stenting

    • Kissing Stents

    • Covered Stent Grafts

    • Endovascular Aortic Repair (EVAR)  

  • Hybrid Procedures

  • Open Surgical Procedures

• Procedure Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Outpatient Facilities

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait